Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (2): 335-339. doi: 10.19723/j.issn.1671-167X.2022.02.022

Previous Articles     Next Articles

Clinicopathologic analysis of micro and mini parotid gland tumors

LI Bing-yu,TANG Zu-nan,HU Lei-hao,ZHANG Wen-bo,YU Yao,YU Guang-yan,PENG Xin()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2020-10-13 Online:2022-04-18 Published:2022-04-13
  • Contact: Xin PENG E-mail:pxpengxin@263.net

Abstract:

Objective: To investigate the clinicopathological characteristics of micro and mini parotid gland tumors and to provide reference for their clinical diagnosis and treatment. Methods: Patients with parotid gland tumors treated in the Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology from December 2012 to April 2020 were selected. Relevant clinical data of the patients with tumor diameter ≤20 mm detected by preoperative CT were collected to analyze the clinicopathological characteristics and prognosis of micro and mini parotid gland tumors. And the collected data were divided into two groups with diameter 11-20 mm and diameter ≤10 mm according to tumor diameter measured by preoperative CT. The clinicopathological differences between the two groups were statistically analyzed. Results: A total of 2 067 patients with primary epithelial parotid gland tumors were collected, and 685 patients with tumor diameter ≤20 mm were examined by CT, accounting for 33.1%. The ratio of male to female patients with micro and mini parotid gland tumors was 1 ∶1.93, the average age was (45.3±13.8) years (12-83 years), and the median course of disease was 12 months (1 week to 30 years). Among them, 635 cases (92.7%) were benign tumors, 50 cases (7.3%) were malignant tumors, and the ratio of benign to malignant was 12.7 ∶1. The most common benign tumor was pleomorphic adenoma, and the most common malignant tumor was mucoepidermoid carcinoma. The micro and mini parotid gland tumors were divided into 11-20 mm group (n=611) and ≤10 mm group (n=74), the clinical characteristics comparison of the two groups of gender ratio, average age, course of di-sease had no statistical difference (P>0.05). In the 11-20 mm diameter group, the percentage of benign and malignant tumor was 92.8% (567/611) and 7.2% (44/611) respectively, and the ratio of benign to malignant tumors was 12.9 ∶1. In the ≤10 mm diameter group, the percentage of benign and malignant tumor was 91.9% (68/74) and 8.1% (6/74) respectively, and the ratio of benign to malignant tumors was 11.3 ∶1. There was no significant difference between the two groups (P>0.05). Fifty patients with malignant tumor were followed up for the median follow-up period of 39.5 months (1-91 months). Local recurrence occurred in 2 patients with one death. The overall 2-year survival rate was 93.7% and the 5-year survival rate was 89.3%. Conclusion: The majority of micro and mini parotid gland tumors was benign lesion. There was a good prognosis for micro and mini parotid gland carcinoma. Early surgical treatment was recommended for micro and mini parotid gland tumors.

Key words: Parotid neoplasms, Tumor size, Pathology, clinical

CLC Number: 

  • R739.87

Table 1

Comparison of parotid neoplasm between size 11-20 mm and ≤10 mm"

Items Diameter of tumor P
11-20 mm (n=611) ≤10 mm (n=74)
Gender (Male/Female) 215/396 19/55 0.103
Age/years 44.0±13.9 47.0±12.9 0.311
Course/months 12.0±38.8 11.0±35.7 0.386

Table 2

Histological types of parotid neoplasm by size of 11-20 mm and ≤10 mm"

Histological types Diameter of tumor Total (n=685)
11-20 mm (n=611) ≤10 mm (n=74)
Benign/Malignant ratio 12.9 ∶1 11.3 ∶1 12.7 ∶1
Benign, n(%)
Pleomorphic adenoma 383 (67.5) 39 (57.4) 422 (66.5)
Basal cell adenoma 96 (16.9) 21 (30.9) 117 (18.4)
Warthin tumor 70 (12.3) 0 70 (11.0)
Cystadenoma 7 (1.2) 2 (2.9) 9 (1.4)
Myoepithelioma 5 (0.9) 3 (4.4) 8 (1.3)
Non sebaceous lymphadenoma 3 (0.5) 0 3 (0.5)
Papillary cystadenoma 1 (0.2) 2 (2.9) 3 (0.5)
Oncocytoma 2 (0.4) 1 (1.5) 3 (0.5)
Total 567 (100.0) 68 (100.0) 635 (100.0)
Malignant, n(%)
Well-differentiated mucoepidermoid carcinoma 17 (38.6) 5 (83.3) 22 (44.0)
Intermediate differentiated mucoepidermoid carcinoma 2 (4.5) 0 2 (4.0)
Acinic cell carcinoma 10 (22.7) 0 10 (20.0)
Adenoid cystic carcinoma 4 (9.1) 0 4 (8.0)
Secretory carcinoma 3 (6.8) 0 3 (6.0)
Salivary duct carcinoma 2 (4.5) 0 2 (4.0)
Oncocytic carcinoma 2 (4.5) 0 2 (4.0)
Adenocarcinoma 1 (2.3) 0 1 (2.0)
Adenocarcinoma, NOS 1 (2.3) 0 1 (2.0)
Basal cell adenocarcinoma 0 1 (16.7) 1 (2.0)
CXPA 1 (2.3) 0 1 (2.0)
Squamous cell carcinoma 1 (2.3) 0 1 (2.0)
Total 44 (100.0) 6 (100.0) 50 (100.0)

Figure 1

Survival curves of parotid neoplasm by tumor size ≤20 mm (n=50)"

[1] 俞光岩, 高岩, 孙永刚, 等. 口腔颌面部肿瘤[M]. 北京: 人民卫生出版社, 2002: 324-381.
[2] 陈志奎, 张秀娟, 黄静, 等. 高频超声诊断腮腺肿瘤[J]. 中国医学影像技术, 2011, 27(9):1775-1778.
[3] 张翔云, 保继荣. 腮腺区肿块影像学综合诊断的临床研究[J]. 广西医科大学学报, 2000, 17(2):231-232.
[4] Altin F, Alimoglu Y, Acikalin RM, et al. Is fine needle aspiration biopsy reliable in the diagnosis of parotid tumors? Comparison of preoperative and postoperative results and the factors affecting accuracy[J]. Braz J Otorhinolaryngol, 2019, 85(3):275-281.
doi: 10.1016/j.bjorl.2018.04.015
[5] 中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016, 43(10):405-411.
[6] 付鹏, 陈文, 崔立刚, 等. 2017版美国放射学会甲状腺影像学报告与数据系统应用价值探索[J]. 北京大学学报(医学版), 2019, 51(6):1067-1070.
[7] El-Naggar AK, Chan JK, Grandis JR, et al. WHO classification of tumors of head and neck tumours[M]. 4th ed. Lyon: IARC Press, 2017: 159-201.
[8] Wong DS. Signs and symptoms of malignant parotid tumours: An objective assessment[J]. J R Coll Surg Edinb, 2001, 46(2):91-95.
pmid: 11329749
[9] Cho HW, Kim J, Choi J, et al. Sonographically guided fine-needle aspiration biopsy of major salivary gland masses: A review of 245 cases[J]. Am J Roentgenol, 2011, 196(5):1160-1163.
doi: 10.2214/AJR.10.4256
[10] Rosai J. ROSAI & ACKERMAN外科病理学[M]. 北京: 北京大学医学出版社, 2014.
[11] Qin S. Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)[J]. Chin Clin Oncol, 2012, 1(1):10.
[12] 宋勇, 姚艳雯. 肺部小结节的诊断和治疗近况[J]. 中华肺部疾病杂志: 电子版, 2012, 5(4):295-299.
[13] Macmahon H. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society[J]. Radiology, 2005, 237(2):395-400.
doi: 10.1148/radiol.2372041887
[14] 王俊, 刘彦国. 肺内小结节的诊治现状、问题和方向[J]. 中华胸心血管外科杂志, 2012, 28(7):385-386.
[15] 凌云, 张明琼, 李芳, 等. 高频彩超、钼靶联合MRI对降低乳腺微小癌漏诊误诊率的价值分析[J]. 检验医学与临床, 2016, 13(21):3004-3005.
[16] 薛杰, 曹小丽, 姜宏, 等. 甲状腺影像报告与数据系统联合超声弹性成像对甲状腺良恶性结节的诊断价值[J]. 中国医学影像学杂志, 2015, 23(5):351-355.
[17] Rago T, Santini F, Scutari M, et al. Elastography: New developments in ultrasound for predicting malignancy in thyroid nodules[J]. J Clin Endocrinol Metab, 2007, 92(8):2917-2922.
doi: 10.1210/jc.2007-0641
[18] 陈少卿, 刘钰, 黎军和, 等. 103例腮腺癌的治疗疗效和预后因素分析[J]. 中国肿瘤临床, 2014, 41(12):797-800.
[19] 皮正超, 李长青. 腮腺恶性肿瘤的术后放疗[J]. 中华放射肿瘤学杂志, 1995, 4(3):173-174.
[20] 温玉明, 陈润良, 王昌美. 腮腺多形性腺瘤腺体切除范围的病理依据[J]. 华西口腔医学杂志, 2003, 21(5):359-360.
[21] 俞光岩, 马大权. 腮腺肿瘤切除术的改进和发展[J]. 中华口腔医学杂志, 2007, 42(1):6-9.
[22] 高敏, 陈艳, 高岩, 等. 紧贴面神经的腮腺多形性腺瘤的临床病理特点及处理[J]. 北京大学学报(医学版), 2012, 44(1):43-46.
[1] XUE Jiang,ZHANG Jian-yun,SHI Rui-rui,XIE Xiao-yan,BAI Jia-ying,LI Tie-jun. Clinicopathological analysis of 105 patients with fibrous dysplasia of cranio-maxillofacial region [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 54-61.
[2] WEI Hui,Luo-zeng ##,Ci-dan-yang-zong ##,Bai-ma-yang-jin ##. Analysis of clinical characteristics of Henoch-Schonlein purpura patients from different altitudes in plateau areas [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1072-1077.
[3] SONG Zhi-bo,GENG Yan,DENG Xue-rong,ZHANG Xiao-hui,ZHANG Zhuo-li. Benefit of ultrasound in the phenotype recognition of psoriatic arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1061-1066.
[4] Mei-ge LIU,Pu FANG,Yan WANG,Lu CONG,Yang-yi FAN,Yuan YUAN,Yan XU,Jun ZHANG,Dao-jun HONG. Clinical, pathological and genetic characteristics of 8 patients with distal hereditary motor neuropathy [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 957-963.
[5] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[6] GAO Yang-xu,SUN Qing,LI Hui,XIE Yao,YAO Hong-xin,ZHAO Wei-hong. Therapeutic effect and clinical cost of multi-disciplinary team model of hepatoblastoma in children [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 200-203.
[7] Yu-zhou GAN,Yu-hui LI,Li-hua ZHANG,Lin MA,Wen-wen HE,Yue-bo JIN,Yuan AN,Zhan-guo LI,Hua YE. Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1001-1008.
[8] Shi-xiong WEI,Shu-jia LI,Yi LIU. Clinical characteristics and biological treatment of adult patient with juvenile idiopathic arthritis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1014-1022.
[9] Gong CHENG,Xia ZHANG,Fei YANG,Jia-yu CHENG,Yan-ying LIU. Angioimmunoblastic T-cell lymphoma with fever, arthritis and skin pigmentation: A case report [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1150-1152.
[10] Zhi-feng XU,Yun-peng LING,Zhong-qi CUI,hong ZHAO,Yi-chen GONG,Yuan-hao FU,Hang YANG,Feng WAN. Feasibility and safety of minimally invasive cardiac coronary artery bypass grafting surgery for patients with multivessel coronary artery disease: Early outcome and short-mid-term follow up results [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 863-869.
[11] Yi LIU,Zhi-jian LIU,Qi SHEN,Jing-yun WU,Yu FAN,De-run LI,Wei YU,Zhi-song HE. A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 621-624.
[12] Yi-chang HAO,Ye YAN,Fan ZHANG,Min QIU,Lang ZHOU,Ke LIU,Jian LU,Chun-lei XIAO,Yi HUANG,Cheng LIU,Lu-lin MA. Surgical strategy selection and experience summary of prostate cancer with positive single needle biopsy [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 625-631.
[13] Ling WEI,Dong ZOU,Hu CHEN,Shao-xia PAN,Yu-chun SUN,Yong-sheng ZHOU. Evaluation of clinical efficacy of a kind of digital complete denture [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 762-770.
[14] Hang-ci ZHENG,Xiao-tong LI,Peng MEN,Xiang MA,Qiang WANG,Yao-long CHEN,Suo-di ZHAI. Selecting and defining the clinical questions and outcomes of Guideline for the Emergency Treatment of Anaphylaxis [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 715-718.
[15] Ru MA,Xin-bao LI,Feng-cai YAN,Yu-lin LIN,Yan LI. Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 240-246.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Xin-yu WANG,Zhe CUI,Qing-yuan HE,Xiang-ning DENG,Ge GUO,Xin-heng FENG,Jie-li FENG. Assessment of heart’s changes of elite Chinese male weightlifter by speckle tracking echocardiography[J]. Journal of Peking University (Health Sciences), 2021, 53(5): 832 -837 .
[2] . [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 1 -6 .
[3] . [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1017 -1019 .
[4] LOU Xue,LIAO Li,LI Xing-jun,WANG Nan,LIU Shuang,CUI Ruo-mei,XU Jian. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis[J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020 -1025 .
[5] ZHONG Hua,XU Li-ling,BAI Ming-xin,SU Yin. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis[J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026 -1031 .
[6] . [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 633 -634 .
[7] . [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 828 -831 .
[8] . [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 635 -639 .
[9] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma[J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640 -646 .
[10] WANG Li-xin , XU Xiao, NI Yao-feng, SUN Hai-tao, YU Ri-yue, WEI Shi-cheng. In vivo study of liposome-modified polyetheretherketone implant on bacteriostasis and osseointegration[J]. Journal of Peking University (Health Sciences), 2021, 53(4): 758 -763 .